XYMOGEN Releases HistDAO For Histamine-Related Digestive System Issues
ORLANDO, Fla. – Thursday, August 16, 2012 – Health sciences leader XYMOGEN announces the release of HistDAO, an exclusive dietary supplement that aids in issues associated with intestinal or negative intolerance to food-derived histamines.*
HistDAO, which is the new name for HistoXYM, supports the healthy degradation of food-derived histamines in the lower intestines.*
Diamine Oxidase (DAO) is the main enzyme associated with metabolizing ingested histamines from foods such as tuna, aged cheese, tomatoes, red wine or champagne. Digestive issues are becoming more common and more problematic as individuals struggle with the discomfort and pain from foods that release histamines.
“Physicians are seeing increasing numbers of patients with digestive issues many of which are diagnosed as histamine triggered,” said Brian Blackburn, President and CEO of XYMOGEN. “HistDAO provides an option for reducing discomfort without creating other health issues since it has no systemic effect and therefore does not tilt the imbalanced body further out of balance.”*
HistDAO can be taken 15 minutes before eating and can help with the degradation of food-derived histamine. Digestive issues are increasing in society and the reasons are attributed to diet and specifically some food additives. HistDAO is gluten-free and lactose-free. While dietary supplements can’t mitigate disease or replace drugs, they can be hugely effective in reducing health issues without creating other problems.*
Newly released HistDAO is available exclusively through XYMOGEN and at reduced prices.
XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties. XYMOGEN’s unprecedented growth continues with a new, state-of-the-art, 136,000 square foot manufacturing facility and laboratory, and a strategic expansion into Canada and Australia, two of the largest international markets. XYMOGEN’s strength as a company was reinforced in 2007, 2008, 2010, and 2011, when it was recognized by Inc. magazine as one of the 5000 fastest-growing private companies in America.
For more information, visit www.xymogen.com
Please email firstname.lastname@example.org for comments or inquiries.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, prevent, or cure any disease.
# # #
Distributed by Sara Brady Public Relations, Inc.
222 W. Comstock Avenue, Suite 215
Winter Park, Florida 32789
For information, contact:
Sara R. Brady